(Date:10/14/2008)... Also debuts TMR,09 campaign, IRVINE, Calif., O...poration (Pink Sheets: CGCP), a global leader of i...nd the market leader of surgical products for,tran...educational symposium,yesterday in conjunction wit...rapeutics (TCT) meeting in Washington, D.C., The ...
(Date:10/14/2008)... more than 500 accounts Company opening new PROMUS...ICK, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Bost...unced estimated U.S. market shares for,September f...liminary data,from Millennium Research Group (MRG)...he healthcare sector., Based on the MRG data, the...
(Date:10/14/2008)... Leading Supplemental Insurance Company Encour... Employee Benefits , Chic...e , a leading provider of supplemental insurance, ...time to review employee benefits and recommends ,V...to help retain employees. These programs can be a ...
(Date:10/14/2008)...ctober 14 /PRNewswire/ -- Researchers at the Insti... started work on a 3.5 year,project to develop a n...hemical vapour deposition) diamond manufactured by...he field of CVD diamond synthesis and its,applicat...uld open up a raft of new,application areas in, fo...
Breaking Medicine News(10 mins):Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 2Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 3Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 4Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 2Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 3Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 2Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 3Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 5Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 2Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 3Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 4(Date:10/14/2008)... 14 /PRNewswire-USNewswire/ -- The Michael J. Fox,...l of $2 million to five,research teams to speed de...ressed cognitive and mood-related symptoms of Park...oms, which range from problems with,executive func...ute plans),to dementia; depression, apathy and anx...
(Date:10/13/2008)... Stent with Polyzene(R)-F Surface Treatment Maximi...ogenicity, Need for Long-Term,Dual Antiplatelet Th...al investigators at today,s,"Innovative Devices an...nual Transcatheter Cardiovascular Therapeutics (TC...scular Research Foundation, presented,12-month fol...
(Date:10/13/2008)...s., Oct. 13 /- Facet Solutions, Inc. ...p on 20 patients from its US,IDE Pilot Study. The ...y,Index (ODI) scores, and an 80% reduction in Visu...eoff Pardo, President & CEO for Facet Solutions,a...s, which thus far not,only demonstrate significant...
(Date:10/10/2008)... MENLO PARK, Calif., Oct. 10 /PRNewswire-FirstCall...that it plans to present,long-term follow-up data ...,week at the Cardiovascular Research Foundation,s ...r Therapeutics (TCT) meeting in Washington, DC.,Th...esigned to investigate,the safety and efficacy of ...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinson's Disease 2Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinson's Disease 3Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinson's Disease 412-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 212-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 312-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 4XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week 2GSA Selects Cascades Technologies Inc 28CTi 29 to Support USA gov 2431 1GSA Selects Cascades Technologies Inc 28CTi 29 to Support USA gov 2431 2FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 1FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 2FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 3FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 4FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 5Kiwa Bio Tech Products Group Holds a Fertilizer Products Exhibition in Hebei 2427 1Kiwa Bio Tech Products Group Holds a Fertilizer Products Exhibition in Hebei 2427 2Kiwa Bio Tech Products Group Holds a Fertilizer Products Exhibition in Hebei 2427 3Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder 1132 1Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder 1132 2Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder 1132 3Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder 1132 4...Improved Outcomes in Carotid,Artery Stenting, ABBO...l/ --,Positive 30-day results from two Abbott stud... with positive results by,physicians with a variet...ical trial) settings in patients who are not favor...the first 1,500,patients enrolled in EXACT (Embosh...
...n Thursday, March 29, 2007,At 2:00 p.m. Pacific T...- MediciNova, Inc.,a biopharmaceutical company th...(Nasdaq:MNOV) and the Hercules Market of the Osaka...ounced positive,clinical findings from the 12-mont...66 that measures both surrogate,(radiological) and...
Other Medicine Technology:Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 2Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 3Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 4MediciNova Announces Positive Clinical Results From MN-166 Phase II,Multiple Sclerosis Trial 2MediciNova Announces Positive Clinical Results From MN-166 Phase II,Multiple Sclerosis Trial 3MediciNova Announces Positive Clinical Results From MN-166 Phase II,Multiple Sclerosis Trial 4MediciNova Announces Positive Clinical Results From MN-166 Phase II,Multiple Sclerosis Trial 5...Mullerian Inhibiting Substance (MIS), also known a...glycoprotein dimer composed of two 72 kDa monomers...to the transforming growth factor-? (TGF-?) superf... and activin glycoproteins (2). All members of thi...
The STA Compact CT is a completely automated, benchtop hemostasis analyzer capable of performing clotting assays in random access mode. The system's unique method of sample management offers high thr
...Alpha Fetoprotein (AFP) is a 68 kDa protein, which...tal liver and yolk sac [1]. Human fetal serum AFP...n rates reach 19-26 g/min during mid-gestation (14...es of total fetal AFP continue to increase after m...
Compensating for movement is critical to weighing patients in wheelchairs. Thats why this scale has the exclusive technology to do just that. Extremely durable, with state-of-the-art technology, thes
Medicine Products: